OMADA HEALTH INC Stock Price, News & Analysis

Omada Health (NASDAQ: OMDA) announced senior management will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

The company will present on Wednesday, Jan. 14, 2026 at 9:00 a.m. PST. A live webcast and subsequent replay will be available at https://investors.omadahealth.com/news-events/events.

Omada Health (Nasdaq: OMDA) announced that senior management will participate in the 8th Annual Evercore Healthcare Conference in Miami.

The company will host a fireside chat on Wednesday, December 3, 2025 at 1:20 pm ET. A live webcast and a replay will be available at https://investors.omadahealth.com/news-events/events.

Omada Health (NASDAQ: OMDA) reported Q3 2025 results: revenue $68.0M (+49% year-over-year) and total members 831,000 (+53% YoY). Gross margin improved to 66% and non-GAAP gross margin to 68%. Omada posted a net loss of $3M versus $9M a year earlier and delivered its first quarter of positive adjusted EBITDA: $2M. Cash and cash equivalents were $199M at September 30, 2025. Management announced a new GLP-1 prescribing offering, launched AI nutrition product Meal Map, and published its 30th peer-reviewed manuscript with weight-maintenance data after GLP-1 discontinuation. Full-year 2025 guidance was raised to $251.5M–$254.5M revenue and adjusted EBITDA of a $2M loss to breakeven.

Omada Health (NASDAQ: OMDA) announced a planned nationwide prescribing capability for anti-obesity medications (AOM), including GLP-1s, to integrate medication management into its evidence-based behavior change weight program.

The company reported 53% year-over-year member growth through Q3 2025 and said the prescribing option will be available in all 50 states. Omada cited published analyses showing a 28% greater weight loss at 4 months in its Enhanced GLP-1 Care Track and 0.8% average weight change 12 months after discontinuation in one analysis versus 11–12% gain in trials.

Omada Health (Nasdaq: OMDA) will present two ObesityWeek 2025 posters (Nov 4-5, 2025) reporting real-world evidence that Omada’s behavior-change program may improve outcomes for members on or previously on GLP-1 medications for weight loss.

Key findings: 84% persistence at 24 weeks (n=1,124) with greater weight loss for persistent users (12.1% vs 7.4%), a 54% higher odds of persistence per 10 additional weekly engagements, and an average 0.8% weight change at 12 months post-discontinuation (n=95), with 63.2% maintaining or losing weight.

Omada Health (Nasdaq: OMDA) appointed Thomas Tsang, MD, MPH as Chief Medical Officer on October 27, 2025. Dr. Tsang will lead clinical quality, outcomes, strategy, and innovation across Omada’s multi-condition virtual care platform.

He brings prior roles including founding CEO of Valera Health (raised >$75 million; scaled to >500 employees), CMO at Merck Healthcare Services and Solutions, and policy roles at the Office of the National Coordinator and the U.S. House Ways and Means Committee. Omada highlights its GLP-1 Care Track serving over 100,000 members, recent AI launches OmadaSpark and Meal Map, and a customer base exceeding 2,000 organizations.

Omada Health (Nasdaq: OMDA) will release third quarter 2025 financial results on Thursday, November 6, 2025, after market close. The company will host a conference call to review results at 4:30 PM ET the same day.

A live audio webcast will be available at https://investors.omadahealth.com. A replay will be posted at the same link shortly after the call and will remain accessible for approximately 12 months. Participants can pre-register for the conference call at the provided registration link.

Omada Health (Nasdaq: OMDA) has launched Meal Map, an innovative AI-powered nutrition tool integrated within their Nutritional Intelligence capability. This new feature provides instant feedback on nutrient composition and focuses on nutrient quality rather than calorie counting.

The tool, piloted with over 1,000 members, showed increased meal engagement compared to traditional approaches. Meal Map combines AI-powered feedback with human care teams, offering weekly progress reports on nutritional quality and water intake, along with dietitian-vetted recipes through OmadaSpark.

This evidence-based approach aims to help members improve their relationship with food, particularly relevant in the context of increased GLP-1 medication use and rising fad diet popularity. The focus on nutrient density has been linked to various health benefits, including improved immune system function, energy levels, digestive health, and reduced risk of cardiovascular diseases.

Omada Health (Nasdaq: OMDA) has released groundbreaking analysis challenging common assumptions about weight regain after GLP-1 medication discontinuation. The study of 816 members showed that 63% of participants maintained or continued losing weight 12 months after stopping GLP-1 medications, with only a 0.8% average weight change compared to typical 11-12% weight gain seen in clinical trials.

The analysis tracked outcomes at 6, 9, and 12 months post-discontinuation, demonstrating consistent weight maintenance throughout the year. Omada has supported over 100,000 members taking GLP-1 medications through their GLP-1 Care Track program, which provides behavioral support, dedicated care teams, connected devices, and an AI-enhanced digital experience.